Dr. Katharina Severin

Investment Manager

Katharina Severin joined the Life Science Team in September of 2021. She was born and raised in the Ruhr area and spent time in the US and Asia during her education. Among these stays was a one-year research stay in the lab of Tom Rapoport at Harvard Medical School in Boston. Katharina obtained her PhD in Medical Biology and received numerous scholarships and awards, among them stipends from the German National Academic Foundation and the Christiane Nüsslein-Volhard Foundation. Through networking opportunities from these foundations and as an attendee of the Lindau Nobel Laureate Meeting, Katharina discovered and cultivated her passion for interdisciplinary scientific exchange. Her research findings mark a starting point for a novel therapeutic approach in the treatment of cancer. Katharina is fascinated by entrepreneurial questions and is passionate about bringing scientific results and genious business ideas to profitable ventures.


Posts & mentions

2. July 2024

DKFZ spin-off Epignostix raises €4.3m Seed round to commercialize diagnostic tumor classifier

Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics today announces €4.3M in seed funding. This investment will enable Heidelberg Epignostix to make a substantial leap forward in driving market development for its flagship indication for brain tumor classification. CARMA FUND I Capital GmbH & Co KG led the round with participation from High-Tech Gründerfonds, LBBW Venture Capital GmbH and Start-up BW Seed Fonds. Heidelberg Epignostix’ technol
19. April 2023

Phialogics secures pre-seed financing for Next-Gen IgV Therapeutics to modulate immune responses in inflammatory diseases

Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. The startup closes a 600,000 € pre-seed financing round with High-Tech Gründerfonds. The capital will be used to further develop Phialogics’ lead candidate in preclinical models in comparison to the current standard of care and other research approaches. This is a step forward to continue developing Phialogics’ i